The identification of the poliovirus receptor (PVR, CD155) as a ligand for KIR2DL5 in 2019 has opened new avenues of research in cancer immunotherapy (Husain et al., 2019), particularly in the context of BC. The gene discussed is PVR; the disease is cancer.